Monitoring heparin treatment with the APTT: The effect of methodological changes on the APTT

Netherlands Journal of Medicine

Volumn 49, Issue 1, 1996, Pages 13-18

  Krulder, J W M ^a,b   Van Der Meer, F J M ^a   Briet E ^a   Meinders, A E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEYENBURG HOSPITAL   (Netherlands)

Author keywords

Activated partial thromboplastin time; Heparin; Laboratory control

Indexed keywords

HEPARIN;

ADOLESCENT; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BOLUS INJECTION; DRUG MONITORING; FEMALE; GOOD LABORATORY PRACTICE; HEMATOLOGICAL PARAMETERS; HOSPITAL PHARMACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0030198446     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/0300-2977(96)00020-4     Document Type: Article

References (24)

1. [1] Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960:i:1309-1312.
2. [2] Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-1264.
3. [3] Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574.
4. [4] Brandjes DPM, Heijboer H, Büller HR, De Rijk M, Jagt H, Ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-1489.
5. [5] Basu D, Callus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:3244-3247.
6. [6] Fennerty AG, Thomas P, Backhouse G, Bentley P, Campbell IA, Routledge PA. Audit of control of heparin treatment. Br Med J 1985;290:27-28.
7. [7] Soloway HB, Cornett BM, Grayson JW. Comparison of various activated partial thromboplastin reagents in the laboratory control of heparin therapy. Am J Clin Pathol 1973;59:587-590.
8. [8] Gawoski JM, Arkin CF, Bovill T, Brandt J, Rock WA, Triplett DA. The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists survey specimens. Arch Pathol Lab Med 1987;111:785-790.
9. [9] Shojania AM, Tetreault J, Tumbull G. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol 1988;89:19-23.
10. [10] Van den Besselaar AMHP, Meeuwisse-Braun J, Bertina RM. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemostas 1990;63:16-23.
11. [11] D'Angelo A, Seveso MP, D'Angelo SV, Gilardoni F, Dettori AG, Bonini P. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Am J Clin Pathol 1990;94:297-306.
12. [12] Wheeler AP, Jaquiss RDB, Newman JH. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med 1988;148:1321-1325.
13. [13] Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991;151:333-337.
14. [14] Krulder JWM. Controle van heparinetherapie met behulp van een APTT. Tijdschr NVKC 1990;15:133-134.
15. [15] Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152:1589-1595.
16. [16] Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-1114.
17. [17] Kershaw B, White RH, Mungall D, Van Houten J, Brettfeld S. Computer-assisted dosing of heparin. Management with a pharmacy-based anticoagulation service. Arch Intern Med 1994;154:1005-1011.
18. [18] Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993;119:874-881.
19. [19] Felding P, Bremmelgaard, Winkel P. Adjusted-dose intravenous heparin treatment. Evaluation of an automated and a non-automated schedule. Thromb Res 1988;51:447-452 .
20. [20] Elliott CG, Hiltunen SJ, Suchyta M, et al. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med 1994;154:999-1004.
21. [21] Decousus HA, Croze M, Levi FA, et al. Circadian changes in anticoagulant effect of heparin infused at a constant rate. Br Med J 1985;290:341-344.
22. [22] Krulder JWM, Van den Besselaar AMHP, Van der Meer FJM, Meinders AE, Briët E. Diurnal changes in heparin effect during continuous constant rate infusion. A study in nine patients with venous thromboembolism. J Intern Med 1994;235:411-417.
23. [23] Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-607.
24. [24] Huisman MV, Büller HR, Ten Gate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989;95:498-502.